Category Archives: otcbb

Vitro Biopharma CEO Letter to Shareholders 2015

11/5/15 VODG went up 121% today after posting this press release


Dear Shareholders:
Concussion and traumatic brain injury (TBI) are significant health risks that lack modern therapeutic approaches beyond physical therapy and rehabilitation. The TBI incidence in the US is 1.5 to 1.7 million new cases per year and is estimated to cost $75 billion per year in the US only. Concussion is a growing issue within professional athletes including the NFL where significant health problems are derived from football-related concussion. Military service personnel and numerous others are also significantly impacted by TBI. We began development of stem cell activation technology and products during 2014 and expanded these activities in during 2015 to include treatment of concussion. We have developed patent-pending technology for treatment of neurological conditions through the activation of stem cells residing within the body. This is a process for administration of stem cell therapeutic benefit without stem cell transplants.

State Bank Corp Announces Stock Repurchase Program

State Bank Corp. (OTCQB:SBAZ), the holding company for Mohave State Bank, today announced that its Board of Directors has authorized the repurchase of up to $1,000,000 of the outstanding common stock of the company. Stock repurchases may be made from time to time on the open market or through privately negotiated transactions. The timing of purchases and the exact number of shares to be purchased will depend on market conditions. The share repurchase program does not include specific price targets or timetables and may be suspended at any time.

“We believe our stock is an attractive investment and repurchasing stock affirms our optimism for the future and offers an excellent means to build long-term value for our shareholders,” said Brian M. Riley, President and CEO. Earlier today, State Bank Corp. reported its second quarter earnings results and provided detailed financial information in a separate press release.

Mikros Systems Announces 2014 Results: Record Profits and Backlog

Revenues Up 80%; Backlog at $5.5M; ADEPT Contract Extended Through August 2016

PRINCETON, N.J., March 31, 2015 (GLOBE NEWSWIRE) — Mikros Systems Corporation (MKRS), an advanced technology company which designs and manufactures specialized electronic systems for the Department of Defense, today announced strong financial results for 2014, including record profits for the year and the largest backlog for future orders in the Company’s history.

Mikros reported revenues of $5.53 million in 2014, compared to $3.05 million in 2013, an increase of $2.48 million or more than 80%. Net income was $533,000 compared to a loss of $147,000 in 2013. As of December 31, 2014, the backlog for future orders stood at $5.5 million, representing the highest backlog in the history of the Company.

“We are delighted to report a return to profitability after surviving a lean 2013 caused primarily by defense budget sequestration cuts and delays,” said Mikros President Tom Meaney. “Not only did Mikros come back with strong operating performance in 2014, we also generated multiple new contracts and task orders under existing contracts and believe our prospects for future growth are as strong as they have ever been. We continue to receive orders for additional production and related support of our ADEPT products, and several important new development contracts which will extend the system to maintain other Navy radars and combat system equipment.”

Data Call Technologies, Inc. Continues to Report Record Sales and Record Operational Profits

FRIENDSWOOD, TX–(Marketwired – Aug 4, 2014) – Data Call Technologies, Inc. (OTCBB: DCLT) (the “Company” or “Data Call”), listed on the OTC Bulletin Board (the “Exchange”), announced its financial results for the quarter ended June 30, 2014.

The company recognized as an industry pioneer since the earlier part of this decade, aggregates and provides fresh, updated news and information (infotainment) feeds include items such as in-game sports scores, weather and traffic information, as well as headline/financial news and information in products custom tailored for the Digital Signage space. The company continues with its steady upward growth.

Data Call today announced its financial results for the Quarter ended June 30, 2014. Revenues for the three months ended June 30, 2014 were $164,713 compared to $157,388 for the three-month period ended June 30, 2013, representing an increase of $7,325 or 4.7% during the same period in the prior year. The increase in revenues was mainly due to additional contracts and clients.

Costs of sales for the three months ended June 30, 2014 were $26,921 compared to $26,348 for the three-month period ended June 30, 2013, which represents an increase of $573. Costs of sales did not increase in direct proportion to an increase in revenues, as costs of sales are directly linked to the bandwidth required to provide the subscription services.

Net loss for the three months ended June 30, 2014 was $9,711 compared to a net loss of $641 for the three-month period ended June 30, 2013. The increase in our net loss is mainly due to the expense of stock options and warrants. Operational Profit for the quarter was $37,895 (2013: $100,307). Operational Profit is calculated by adding back the expense for non-cash items such as shares issued for services.

Vitro Biopharma Revenues Increase in Early 2014: Plans Trials of Endogenous Stem Cell Activation for Therapeutic Benefit

Golden, Colorado / February 11, 2013 / ACCESSWIRE / Vitro Diagnostics, Inc. (VODG), dba Vitro Biopharma, announced that its revenues increased substantially (78%, unaudited) in its first 2014 fiscal quarter due to its growing and expanding business relationship with Neuromics, Inc. Vitro Biopharma has now commercialized bio-analytical services as the initial stage in its expansion as a Contract Research Organization (CRO). The services now available include select and customized biomarker panel analysis providing customers quantitative levels of multiple biological molecules within various biological samples. The new business involves analysis of human serum samples collected from patients within a network of clinical treatment centers throughout central Europe. Our partner for these services is Joseph Smarta, Ph.D., a renowned immunologist who has orchestrated treatment of many patients suffering from a variety of diseases. While the analyses are for research purposes only, serial analysis of patients are provided to monitor status and indicate therapeutic effectiveness.